Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by ualcin1on Jun 16, 2021 5:01pm
103 Views
Post# 33399334

Liminal's stock price

Liminal's stock price
As I said last week, the market has not given any kind of importance to the approval of Ryplazim. I expected this stock to trend toward near zero value over time. I see that the evolution of its price since the famous approval is moving inexorably towards that. To be more precise, and unless something spectacularly positive happens in the next few weeks/months, I predict that by the end of the month (week?), Liminal's stock should be around $3.50, around $2 at the end of July, and certainly under $1 in August. And a few cents in September. As for Piper's $4.50 forecast, I find it laughable and more importantly, without any kind of support from concrete facts or serious expectations.
<< Previous
Bullboard Posts
Next >>